Country: Կանադա
language: անգլերեն
source: Health Canada
FULVESTRANT
EUGIA PHARMA INC.
L02BA03
FULVESTRANT
50MG
SOLUTION
FULVESTRANT 50MG
INTRAMUSCULAR
100
Prescription
Active ingredient group (AIG) number: 0149744001; AHFS:
APPROVED
2023-03-28
Page 1 of 37 PRODUCTMONOGRAPH Pr FulvestrantInjection 50 mg/mL Intramuscular Nonagonist EstrogenReceptor Antagonist EugiaPharma Inc. 3700 SteelesAvenueWest,Suite # 402 Woodbridge,Ontario L4L8K8 SubmissionControlNo.: 272653 Date of Preparation: MAR 28, 2023 Page 2 of 37 Table of Contents PARTI: HEALTH PROFESSIONAL INFORMATION ................................................3 SUMMARY PRODUCT INFORMATION ......................................................................3 INDICATIONSAND CLINICAL USE............................................................................3 CONTRAINDICATIONS .................................................................................................3 WARNINGS AND PRECAUTIONS ...............................................................................3 ADVERSE REACTIONS .................................................................................................6 DRUG INTERACTIONS ...............................................................................................12 DOSAGE AND ADMINISTRATION............................................................................12 OVERDOSAGE..............................................................................................................14 ACTION AND CLINICAL PHARMACOLOGY ..........................................................15 STORAGE AND STABILITY .......................................................................................17 DOSAGE FORMS, COMPOSITION AND PACKAGING ...........................................17 PARTII: SCIENTIFIC INFORMATION .....................................................................19 PHARMACEUTICAL INFORMATION .......................................................................19 CLINICAL TRIALS .......................................................................................................19 DETAILEDPHARMACOLOGY...................................................................................30 TOXICOLOGY................................................. read_full_document